BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Do TP, Hvedstrup J, Schytz HW. Botulinum toxin: A review of the mode of action in migraine. Acta Neurol Scand 2018;137:442-51. [PMID: 29405250 DOI: 10.1111/ane.12906] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Freitag FG. Headache Medicine Grand Challenge: Headache: A New Frontier, A New Challenge. Front Pain Res (Lausanne) 2021;2:690683. [PMID: 35295521 DOI: 10.3389/fpain.2021.690683] [Reference Citation Analysis]
2 Kara M, Kaymak B, Sekizkardeş M, Özçakar L. The effects/injections of botulinum toxin in chronic migraine headache. Acta Neurol Scand 2018;138:99. [PMID: 29882965 DOI: 10.1111/ane.12939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Moreno-Ajona D, Hoffmann J. From basic mechanisms to therapeutic perspectives in cluster headache. Curr Opin Neurol 2022;35:336-42. [PMID: 35674077 DOI: 10.1097/WCO.0000000000001055] [Reference Citation Analysis]
4 Olla D, Sawyer J, Sommer N, Moore JB. Migraine Treatment. Clinics in Plastic Surgery 2020;47:295-303. [DOI: 10.1016/j.cps.2020.01.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Webster KE, Harrington-benton NA, Judd O, Kaski D, Maarsingh OR, Mackeith S, Ray J, Van Vugt VA, Burton MJ; Cochrane ENT Group. Pharmacological interventions for prophylaxis of vestibular migraine. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd015187] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Martinelli D, Arceri S, Tronconi L, Tassorelli C. Chronic migraine and Botulinum Toxin Type A: Where do paths cross? Toxicon 2020;178:69-76. [PMID: 32250749 DOI: 10.1016/j.toxicon.2020.02.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Edvinsson JCA, Viganò A, Alekseeva A, Alieva E, Arruda R, De Luca C, D'Ettore N, Frattale I, Kurnukhina M, Macerola N, Malenkova E, Maiorova M, Novikova A, Řehulka P, Rapaccini V, Roshchina O, Vanderschueren G, Zvaune L, Andreou AP, Haanes KA; European Headache Federation School of Advanced Studies (EHF-SAS). The fifth cranial nerve in headaches. J Headache Pain 2020;21:65. [PMID: 32503421 DOI: 10.1186/s10194-020-01134-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
8 Dima L, Bălan A, Moga MA, Dinu CG, Dimienescu OG, Varga I, Neculau AE. Botulinum Toxin a Valuable Prophylactic Agent for Migraines and a Possible Future Option for the Prevention of Hormonal Variations-Triggered Migraines. Toxins (Basel) 2019;11:E465. [PMID: 31398813 DOI: 10.3390/toxins11080465] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
9 Shaterian N, Shaterian N, Ghanaatpisheh A, Abbasi F, Daniali S, Jahromi MJ, Sanie MS, Abdoli A, De Tommaso M. Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review. Pain Research and Management 2022;2022:1-15. [DOI: 10.1155/2022/3284446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Digre KB. What's New in the Treatment of Migraine? Journal of Neuro-Ophthalmology 2019;39:352-9. [DOI: 10.1097/wno.0000000000000837] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
11 Do TP, Heldarskard GF, Kolding LT, Hvedstrup J, Schytz HW. Myofascial trigger points in migraine and tension-type headache. J Headache Pain 2018;19:84. [PMID: 30203398 DOI: 10.1186/s10194-018-0913-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 8.8] [Reference Citation Analysis]
12 Peek AL, Leaver AM, Foster S, Puts NA, Oeltzschner G, Henderson L, Galloway G, Ng K, Refshauge K, Rebbeck T. Increase in ACC GABA+ levels correlate with decrease in migraine frequency, intensity and disability over time. J Headache Pain 2021;22:150. [PMID: 34903165 DOI: 10.1186/s10194-021-01352-1] [Reference Citation Analysis]
13 Chiu SY, Burns MR, Malaty IA. An Update on Botulinum Toxin in Neurology. Neurol Clin 2021;39:209-29. [PMID: 33223084 DOI: 10.1016/j.ncl.2020.09.014] [Reference Citation Analysis]
14 Wang C, Sun Y, Zhao Q. A sensitive thrombin-linked sandwich immunoassay for protein targets using high affinity phosphorodithioate modified aptamer for thrombin labeling. Talanta 2020;207:120280. [PMID: 31594565 DOI: 10.1016/j.talanta.2019.120280] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
15 Reddy AG, Dick BP, Natale C, Akula KP, Yousif A, Hellstrom WJG. Application of Botulinum Neurotoxin in Male Sexual Dysfunction: Where Are We Now? Sex Med Rev 2021;9:320-30. [PMID: 32641225 DOI: 10.1016/j.sxmr.2020.05.004] [Reference Citation Analysis]
16 Zirovich MD, Pangarkar SS, Manh C, Chen L, Vangala S, Elashoff DA, Izuchukwu IS. Botulinum Toxin Type A for the Treatment of Post-traumatic Headache: A Randomized, Placebo-Controlled, Cross-over Study. Mil Med 2021;186:493-9. [PMID: 33241323 DOI: 10.1093/milmed/usaa391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Poulain B, Lemichez E, Popoff MR. Neuronal selectivity of botulinum neurotoxins. Toxicon 2020;178:20-32. [PMID: 32094099 DOI: 10.1016/j.toxicon.2020.02.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
18 Freeman MD, Margulies IG, Sanati-mehrizy P, Burish N, Taub PJ. Nonaesthetic Applications for Botulinum Toxin in Plastic Surgery. Plastic & Reconstructive Surgery 2020;146:157-70. [DOI: 10.1097/prs.0000000000006908] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Voloshin AG, Moiseeva IV. Combined Interventional Treatment of Refractory Chronic Migraine. SN Compr Clin Med 2021;3:1320-6. [DOI: 10.1007/s42399-021-00868-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
20 Li GP, Wang XY, Zhang Y. Efficacy and Safety of OnabotulinumtoxinA in Patients With Neurogenic Detrusor Overactivity Caused by Spinal Cord Injury: A Systematic Review and Meta-analysis. Int Neurourol J 2018;22:275-86. [PMID: 30599499 DOI: 10.5213/inj.1836118.059] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
21 Yoo Y, Lee CS, Kim J, Jo D, Moon JY. Botulinum Toxin Type A for Lumbar Sympathetic Ganglion Block in Complex Regional Pain Syndrome: A Randomized Trial. Anesthesiology 2021. [PMID: 34890455 DOI: 10.1097/ALN.0000000000004084] [Reference Citation Analysis]
22 She T, Chen Y, Tang T, Chen M, Zheng H. Calcitonin gene-related peptide antagonists versus botulinum toxin A for the preventive treatment of chronic migraine protocol of a systematic review and network meta-analysis: A protocol for systematic review. Medicine (Baltimore) 2020;99:e18929. [PMID: 32000407 DOI: 10.1097/MD.0000000000018929] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Frampton JE, Silberstein S. OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine. Drugs 2018;78:589-600. [PMID: 29532439 DOI: 10.1007/s40265-018-0894-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 9.3] [Reference Citation Analysis]
24 Silvestro M, Tessitore A, Scotto di Clemente F, Battista G, Tedeschi G, Russo A. Additive Interaction Between Onabotulinumtoxin-A and Erenumab in Patients With Refractory Migraine. Front Neurol 2021;12:656294. [PMID: 33897608 DOI: 10.3389/fneur.2021.656294] [Reference Citation Analysis]
25 Bendtsen L, Sacco S, Ashina M, Mitsikostas D, Ahmed F, Pozo-Rosich P, Martelletti P. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain 2018;19:91. [PMID: 30259200 DOI: 10.1186/s10194-018-0921-8] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 13.0] [Reference Citation Analysis]